{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:55:29Z","timestamp":1794293729589,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03754-8","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:52:49Z","timestamp":1781830369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study)"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0534-8650","authenticated-orcid":false,"given":"Marie","family":"Najean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9758-3623","authenticated-orcid":false,"given":"Elise","family":"Arnee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4642-0184","authenticated-orcid":false,"given":"Malamati","family":"Voulgaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementine","family":"Dillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4619-265X","authenticated-orcid":false,"given":"Xavier","family":"Ansolabehere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3301-2862","authenticated-orcid":false,"given":"Maxime","family":"Doublet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Chollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3465-8180","authenticated-orcid":false,"given":"Sylvie","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-3461","authenticated-orcid":false,"given":"Stephane","family":"Jouneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"3754_CR1","doi-asserted-by":"publisher","unstructured":"Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur respiratory review: official J Eur Respiratory Soc. 2019;28. https:\/\/doi.org\/10.1183\/16000617.0100-2018.","DOI":"10.1183\/16000617.0100-2018"},{"key":"3754_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00158-2025","author":"CJ Ryerson","year":"2025","unstructured":"Ryerson CJ, Adegunsoye A, Piciucchi S, Hariri LP, Khor YH, Wijsenbeek MS, et al. Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS\/ATS statement. Eur Respir J. 2025. https:\/\/doi.org\/10.1183\/13993003.00158-2025.","journal-title":"Eur Respir J"},{"key":"3754_CR3","doi-asserted-by":"publisher","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020;56. https:\/\/doi.org\/10.1183\/13993003.02279-2019.","DOI":"10.1183\/13993003.02279-2019"},{"key":"3754_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","volume":"19","author":"A Guenther","year":"2018","unstructured":"Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19:141. https:\/\/doi.org\/10.1186\/s12931-018-0845-5.","journal-title":"Respir Res"},{"key":"3754_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s2213-2600(16)30326-5","volume":"5","author":"SD Nathan","year":"2017","unstructured":"Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respiratory Med. 2017;5:33\u201341. https:\/\/doi.org\/10.1016\/s2213-2600(16)30326-5.","journal-title":"Lancet Respiratory Med"},{"key":"3754_CR6","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399st","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347. https:\/\/doi.org\/10.1164\/rccm.202202-0399st.","journal-title":"Am J Respir Crit Care Med"},{"key":"3754_CR7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/nejmoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and santifibroticety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382. https:\/\/doi.org\/10.1056\/nejmoa1402584.","journal-title":"N Engl J Med"},{"key":"3754_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/nejmoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392. https:\/\/doi.org\/10.1056\/nejmoa1402582.","journal-title":"N Engl J Med"},{"key":"3754_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000448288","volume":"92","author":"F Bonella","year":"2016","unstructured":"Bonella F, Kreuter M, Hagmeyer L, Neurohr C, Keller C, Kohlhaeufl MJ, et al. Insights from the german compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respir Int Rev Thorac Dis. 2016;92:98\u2013106. https:\/\/doi.org\/10.1159\/000448288.","journal-title":"Respir Int Rev Thorac Dis"},{"key":"3754_CR10","doi-asserted-by":"publisher","unstructured":"Wright WA, Crowley LE, Parekh D, Crawshaw A, Dosanjh DP, Nightingale P, et al. Real-world retrospective observational study exploring the effectiveness and santifibroticety of antifibrotics in idiopathic pulmonary fibrosis. BMJ open respiratory Res. 2021;8. https:\/\/doi.org\/10.1136\/bmjresp-2020-000782.","DOI":"10.1136\/bmjresp-2020-000782"},{"key":"3754_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","volume":"21","author":"JP Finnerty","year":"2021","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021;21:411. https:\/\/doi.org\/10.1186\/s12890-021-01783-1.","journal-title":"BMC Pulm Med"},{"key":"3754_CR12","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1007\/s12325-023-02454-9","volume":"40","author":"AJ Podolanczuk","year":"2023","unstructured":"Podolanczuk AJ, Cottin V. A narrative review of real-world data on the santifibroticety of nintedanib in patients with idiopathic pulmonary fibrosis. Adv therapy. 2023;40:2038\u201350. https:\/\/doi.org\/10.1007\/s12325-023-02454-9.","journal-title":"Adv therapy"},{"key":"3754_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/s2213-2600(18)30339-4","volume":"7","author":"B Crestani","year":"2019","unstructured":"Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, et al. Long-term santifibroticety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respiratory Med. 2019;7:60\u20138. https:\/\/doi.org\/10.1016\/s2213-2600(18)30339-4.","journal-title":"Lancet Respiratory Med"},{"key":"3754_CR14","doi-asserted-by":"publisher","unstructured":"Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, et al. Pirfenidone santifibroticety and adverse event management in idiopathic pulmonary fibrosis. Eur respiratory review: official J Eur Respiratory Soc. 2017;26. https:\/\/doi.org\/10.1183\/16000617.0057-2017.","DOI":"10.1183\/16000617.0057-2017"},{"key":"3754_CR15","doi-asserted-by":"publisher","unstructured":"Cottin V, Koschel D, G\u00fcnther A, Albera C, Azuma A, Sk\u00f6ld CM et al. Long-term santifibroticety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ open Res. 2018;4. https:\/\/doi.org\/10.1183\/23120541.00084-2018.","DOI":"10.1183\/23120541.00084-2018"},{"key":"3754_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12931-021-01714-y","volume":"22","author":"M Belhassen","year":"2021","unstructured":"Belhassen M, Dalon F, Nolin M, Ganse EV. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respir Res. 2021;22:135. https:\/\/doi.org\/10.1186\/s12931-021-01714-y.","journal-title":"Respir Res"},{"key":"3754_CR17","doi-asserted-by":"publisher","unstructured":"Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, et al. Differential discontinuation profiles between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Cells. 2022;11. https:\/\/doi.org\/10.3390\/cells11010143.","DOI":"10.3390\/cells11010143"},{"key":"3754_CR18","doi-asserted-by":"publisher","first-page":"1586197","DOI":"10.3389\/fphar.2025.1586197","volume":"16","author":"S Majewski","year":"2025","unstructured":"Majewski S, G\u00f3rska K, Lewandowska KB, Martusewicz-Boros MM, Sobiecka M, Piotrowski WJ. Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland. Front Pharmacol. 2025;16:1586197. https:\/\/doi.org\/10.3389\/fphar.2025.1586197.","journal-title":"Front Pharmacol"},{"key":"3754_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1513\/annalsats.202404-430rl","volume":"22","author":"T Kulkarni","year":"2025","unstructured":"Kulkarni T, Flaherty K, Gupta S, Tu Y-H, Case AH. Persistence of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: a pulmonary fibrosis foundation patient registry study. Ann Am Thorac Soc. 2025;22:165\u20138. https:\/\/doi.org\/10.1513\/annalsats.202404-430rl.","journal-title":"Ann Am Thorac Soc"},{"key":"3754_CR20","doi-asserted-by":"publisher","first-page":"e001687","DOI":"10.1136\/bmjresp-2023-001687","volume":"11","author":"ADR Ortiz","year":"2024","unstructured":"Ortiz ADR, Jim\u00e9nez-Rodr\u00edguez BM, Ram\u00edrez CL-, Bauz\u00e1 \u00c1L-, Morales MP-, Delgado-Torralbo JA, et al. Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study. BMJ Open Respir Res. 2024;11:e001687. https:\/\/doi.org\/10.1136\/bmjresp-2023-001687.","journal-title":"BMJ Open Respir Res"},{"key":"3754_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/08971900211008625","volume":"35","author":"F Santoleri","year":"2022","unstructured":"Santoleri F, Auriemma L, Spacone A, Marinari S, Esposito F, Vita FD, et al. Adherence, persistence, and effectiveness in real life. multicenter long-term study on the use of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis. J Pharm Pr. 2022;35:853\u20138. https:\/\/doi.org\/10.1177\/08971900211008625.","journal-title":"J Pharm Pr"},{"key":"3754_CR22","doi-asserted-by":"publisher","first-page":"175346661987289","DOI":"10.1177\/1753466619872890","volume":"13","author":"K Oishi","year":"2019","unstructured":"Oishi K, Hirano T, Murata Y, Hamada K, Uehara S, Suetake R, et al. Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study. Ther Adv Respir Dis. 2019;13:1753466619872890. https:\/\/doi.org\/10.1177\/1753466619872890.","journal-title":"Ther Adv Respir Dis"},{"key":"3754_CR23","doi-asserted-by":"publisher","DOI":"10.1513\/annalsats.202506-645le","author":"J Borr\u00e1s-Blasco","year":"2025","unstructured":"Borr\u00e1s-Blasco J, Valcuende-Rosique A, Cornejo S. How adherence shapes persistence in IPF treatment: a call for real-world insight. Annals Am Thorac Soc. 2025. https:\/\/doi.org\/10.1513\/annalsats.202506-645le.","journal-title":"Annals Am Thorac Soc"},{"key":"3754_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3389\/fphar.2018.01353","volume":"9","author":"I Hurtado-Navarro","year":"2018","unstructured":"Hurtado-Navarro I, Garc\u00eda-Sempere A, Rodr\u00edguez-Bernal C, Santa-Ana-Tellez Y, Peir\u00f3 S, Sanf\u00e9lix-Gimeno G. Estimating adherence based on prescription or dispensation information: impact on thresholds and outcomes. a real-world study with atrial fibrillation patients treated with oral anticoagulants in Spain. Front Pharmacol. 2018;9:1353. https:\/\/doi.org\/10.3389\/fphar.2018.01353.","journal-title":"Front Pharmacol"},{"key":"3754_CR25","doi-asserted-by":"publisher","first-page":"e0166462","DOI":"10.1371\/journal.pone.0166462","volume":"12","author":"V Cottin","year":"2017","unstructured":"Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Lay KL, et al. Burden of idiopathic pulmonary fibrosis progression: a 5-year longitudinal follow-up study. PLoS ONE. 2017;12:e0166462. https:\/\/doi.org\/10.1371\/journal.pone.0166462.","journal-title":"PLoS ONE"},{"key":"3754_CR26","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12890-023-02630-1","volume":"23","author":"J Kaunisto","year":"2023","unstructured":"Kaunisto J, Salomaa E-R, Koivisto M, Myll\u00e4rniemi M. Overall drug treatment of idiopathic pulmonary fibrosis patients from national registries - a real-world study from Finland. BMC Pulm Med. 2023;23:364. https:\/\/doi.org\/10.1186\/s12890-023-02630-1.","journal-title":"BMC Pulm Med"},{"key":"3754_CR27","doi-asserted-by":"publisher","unstructured":"Near AM, Burudpakdee C, Viswanathan S, Kaila S. Effect of a patient support program for idiopathic pulmonary fibrosis patients on medication persistence: a retrospective database analysis. Advances in therapy. 2021;38:3888\u201399. https:\/\/doi.org\/10.1007\/s12325-021-01768-w.","DOI":"10.1007\/s12325-021-01768-w"},{"key":"3754_CR28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/07853890.2023.2179659","volume":"55","author":"HJ Jang","year":"2023","unstructured":"Jang HJ, Woo A, Kim SY, Yong SH, Park Y, Chung K, et al. Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease. Ann Med. 2023;55:663\u201371. https:\/\/doi.org\/10.1080\/07853890.2023.2179659.","journal-title":"Ann Med"},{"key":"3754_CR29","doi-asserted-by":"publisher","first-page":"699532","DOI":"10.3389\/fmed.2021.699532","volume":"8","author":"V Cottin","year":"2021","unstructured":"Cottin V, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, et al. Epidemiology, mortality and healthcare resource utilization associated with systemic sclerosis-associated interstitial lung disease in France. Front Med. 2021;8:699532. https:\/\/doi.org\/10.3389\/fmed.2021.699532.","journal-title":"Front Med"},{"key":"3754_CR30","doi-asserted-by":"publisher","first-page":"100948","DOI":"10.1016\/j.resmer.2022.100948","volume":"83","author":"V Cottin","year":"2023","unstructured":"Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis\u2009\u2013\u20092021 update. Full-length version. Respiratory Med Res. 2023;83:100948. https:\/\/doi.org\/10.1016\/j.resmer.2022.100948.","journal-title":"Respiratory Med Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03754-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:50:37Z","timestamp":1788216637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03754-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3754"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03754-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vincent Cottin has served as a speaker for Boehringer Ingelheim, Ferrer\/United Therapeutics, and Sanofi; as a consultant for AbbVie, AstraZeneca, Avalyn, Boehringer Ingelheim, Bristol Myers Squibb, CSL (Behring, Vifor), Ferrer\/United Therapeutics, Gossamer, GlaxoSmithKline, Liquidia, Pliant, Pulmovant, PureTech, Roche, and Sanofi; has served on Data Safety Monitoring Boards for Calluna, GlaxoSmithKline and Molecure; and has received support for attending meetings from Boehringer Ingelheim and Sanofi. Marie Najean, Cl\u00e9mentine Dillard, Julien Chollet are employed by Boehringer Ingelheim France. Malamati Voulgaridou was employed by Boehringer Ingelheim France at the time of the study. Elise Arnee, Xavier Ansolabehere and Maxime Doublet are employed by Clinityx, which was contracted by Boehringer Ingelheim for the design, monitoring, data management and statistical analysis of the study. Sylvie Leroy has served as a speaker for Boehringer Ingelheim, Astra-Zeneca, and Sanofi; as a consultant for Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche, and Sanofi; as investigator for clinical trials in ILDs for Boehringer Ingelheim, Bristol Myers Squibb, Pliant, Roche, Sanofi and has received support for attending meetings from Astra-Zeneca, Boehringer Ingelheim and CSL-Behring. St\u00e9phane Jouneau has received fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups, research projects over the past 5 years from Abbvie, Agomab, AIRB, Astra Zeneca, Avalyn, Biosency, BMS, Boehringer Ingelheim, Calluna Pharma, Contineum Therapeutics, DevPro, Endeavor Biomedicine, Galacto, GSK, Mediar Therapeutics, Pliant Therapeutics, Pure Tech Health, Syndax, Roche, United Therapeutics, and Savara.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"337"}}